A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples